Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dicerna Pharmaceuticals, Inc., a Novo Nordisk company sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company: 13 sponsored US clinical trials, 2 recruiting.

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Tumor, with 1 trials.

Top-decile sponsor footprint

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

NCT06504368
RECRUITING Phase 2

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

NCT04580420
ACTIVE NOT RECRUITING Phase 3

Long Term Extension Study in Patients With Primary Hyperoxaluria

NCT04042402
COMPLETED Phase 1

A Study of DCR-STAT3 in Adults With Solid Tumors

NCT06098651
COMPLETED Phase 1

Phase 1b Study of DCR-AUD in Healthy Volunteers

NCT05845398
COMPLETED Phase 2

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

NCT05001269
COMPLETED Phase 1

Study of DCR-AUD in Healthy Volunteers

NCT05021640
COMPLETED

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590
TERMINATED Phase 2

A Study of Belcesiran in Patients With AATLD

NCT04764448
COMPLETED Phase 1

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486
COMPLETED Phase 1

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
TERMINATED Phase 1

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052
TERMINATED Phase 1

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

NCT02110563

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 3
Phase 3 1

Therapeutic Areas

Refractory Tumor 1
Primary Hyperoxaluria Type 3 (PH3) 1
Primary Hyperoxaluria Type 2 (PH2) 1
Primary Hyperoxaluria Type 1 (PH1) 1
Primary Hyperoxaluria Type 1 1
Solid Tumors, Adult 1
Urologic Diseases 1
Genetic Disease 1
End Stage Renal Disease 1
Kidney Diseases 1

What is open in the Dicerna Pharmaceuticals, Inc., a Novo Nordisk company pipeline

2 recruiting of 13 indexed (15% open); 7 completed (54%).

Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Refractory Tumor (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company: open-pipeline peers nationwide

Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%5%10%15%20% Total trials Recruiting share Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyAdaptimmuneAgennixAkili Interactive LabsAlumisArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterCandel Therapeutics
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Dicerna Pharmaceuticals, Inc., a Novo Nordisk company page

13 registered trials is a research-attention snapshot, not an endorsement of Dicerna Pharmaceuticals, Inc., a Novo Nordisk company or any single study.

  • 2 of Dicerna Pharmaceuticals, Inc., a Novo Nordisk company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Refractory Tumor is the condition Dicerna Pharmaceuticals, Inc., a Novo Nordisk company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company pipeline card: 13 registered trials from official public datasets.Report a data error.